<DOC>
	<DOCNO>NCT00315757</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( disease response ) safety mapatumumab combination bortezomib bortezomib alone subject relapse refractory multiple myeloma ( MM ) .</brief_summary>
	<brief_title>Study Mapatumumab Combination With Bortezomib ( Velcade ) Bortezomib Alone Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosed multiple myeloma refractory relapse treatment Measurable serum and/or urine Mprotein Failed 1 2 prior therapy multiple myeloma 18 year age old Received 2 prior therapy multiple myeloma . Previous cancer therapy ( chemotherapy , biologic therapy , radiation therapy immunosuppressant ) within last 3 week Received monoclonal antibody within last 3 week ( chimeric murine ) 8 week ( human humanize ) Received investigational ( yet approve regulatory authority ) agent treat multiple myeloma within last 4 week Subjects receive stem cell transplant use cell past 16 week Subjects receive stem cell transplant use cell another individual Previously treat bortezomib mapatumumab Known HIV , hepatitisB , hepatitisC , hepatitis A infection Infection require antibiotic hospitalization within last 2 week Major surgery within last 4 week Diagnosis POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ) History cancer within past 5 year Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>